BCRX

Rating buyAI Memo

BioCryst

As of 2026-09-09/Confidence medium/Horizon 12‑24m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-09 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

buy

Confidence

medium

Horizon

12‑24m

Key catalyst

ORLADEYO pediatric oral-pellet rollout • 2026-09-30

Base target: $12 / p=1% prob

Biggest risk

The pediatric launch still lacks proven paid conversion and real-world outcomes, while early-stage BCX17725 and navenibart carry clinical and timing risk. A recent news headline describing a PHVS trial win may signal increased HAE competition, but the packet lacks primary confirmation. Analyst estimate revisions and target changes after the Q2 print are unavailable.

Invalidation

Break below $7 or thesis failure.

What would change my mind?

ORLADEYO remains the commercial foundation, with pediatric pellets adding a potential uptake channel; management also cites cash generation, completed navenibart enrollment, and year-end BCX17725 data as pipeline supports. Q2 revenue was reported at $218.3 million and full-year 2026 total-revenue guidance was raised to $690-$715 million. [#SEC-8K-2026-08-05] [#PR-EARNINGS-2026-08-12]

Research note

Recommendation

buy

Confidence

medium

As of

2026-09-09

Base target

$12

p=1%

Bull target

$16

p=0%

Bear target

p=0%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

BCX17725 Netherton syndrome data
Navenibart development progression
ORLADEYO remains the commercial foundation, with pediatric pellets adding a potential uptake channel; management also cites cash generation, completed navenibart enrollment, and year-end BCX17725 data as pipeline supports.

BearKey bullets

BCX17725 is an early clinical program and year-end data could disappoint or be delayed.
HAE competitive pressure may increase; the packet includes an unconfirmed headline about a PHVS trial win.
Navenibart readout timing and efficacy remain unresolved despite completed enrollment.

WatchKey bullets

ORLADEYO pediatric oral-pellet rollout

Summary

High-level snapshot

Recommendation

buy

Model confidence

medium

Timeframe

12‑24m

Asset

Equity

Trigger

Base case: $12 (p=1%)

Target spread vs base: +39% / -43%

Scenario probabilities

Bull Target: $16 (p=0%)Base Target: $12 (p=1%)Bear Target: $7 (p=0%)

Commentary

The Q2 earnings transcript is constructive on revenue growth, cash generation, ORLADEYO demand, pediatric rollout, and pipeline execution. However, the September 8 news flow was mixed with a negative headline tied to a reported PHVS trial win. Exact post-release price reaction, analyst revisions, options skew, short interest, employee sentiment, and social coverage were not supplied; missing data is not positive evidence. [#PR-EARNINGS-2026-08-12]

As of 2026-09-09 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

BCX17725 Netherton syndrome data
Navenibart development progression

Scenarios

Bull Target (Scenario probability)

$16 / p=0% prob

Base Target (Scenario probability)

$12 / p=1% prob

Bear Target (Scenario probability)

$7 / p=0% prob

Analysis 2026-09-09 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.10

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-09-30
ORLADEYO pediatric oral-pellet rollout
Pediatric oral-pellet shipments began in early August; management reported 47 prescriptions through July 31 and strong initial authorization activity, while paid conversion and real-world outcomes remain unproven. [#SEC-8K-2026-08-05] [#PR-EARNINGS-2026-08-12]
Prob 75.00% • Move 8.00% • Priced-in 60.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

BCX17725 Netherton syndrome data
2026-12-31
Management said the proof-of-concept trial is enrolling well and expects data by year-end 2026. This is an early clinical program with meaningful development risk. [#PR-EARNINGS-2026-08-12]
Prob 55% • Move 12% • Priced-in 35%
Navenibart development progression
2027-03-31
Management reported completion of enrollment in the largest blinded HAE trial to date. Future readout timing and efficacy data remain key unresolved value drivers. [#PR-EARNINGS-2026-08-12]
Prob 60% • Move 15% • Priced-in 30%

Risks

BCX17725 is an early clinical program and year-end data could disappoint or be delayed.
HAE competitive pressure may increase; the packet includes an unconfirmed headline about a PHVS trial win.
Navenibart readout timing and efficacy remain unresolved despite completed enrollment.
Pediatric ORLADEYO pellet demand, paid conversion, and real-world outcomes remain unproven.
Post-earnings analyst revisions, consensus surprise data, options positioning, and short interest were not supplied.
SEC Form 4 records include insider selling, but insider activity is not evidence of operating performance. [#SEC-FORM4-2026-05-19] [#SEC-FORM4-2026-05-15]

Peers

Symbol	Summary
PHVS	Closest listed HAE-focused comparator and relevant commercial/development peer; recent packet headlines indicate a PHVS trial win, increasing competitive monitoring risk, but primary confirmation and detailed comparative economics are unavailable.
COAG	Similarly sized rare-disease biotechnology company, but the packet provides no operating metrics, making the comparison loose.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-09

Loading AI feed…

Symbol

Summary

PHVS

Closest listed HAE-focused comparator and relevant commercial/development peer; recent packet headlines indicate a PHVS trial win, increasing competitive monitoring risk, but primary confirmation and detailed comparative economics are unavailable.

COAG

Similarly sized rare-disease biotechnology company, but the packet provides no operating metrics, making the comparison loose.